Actualités UCB (PK) - UCBJY | Actions OTCMarkets

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at American College of Gastroenterology 2014 Annual Sci...

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at American College of Gastroenterology 2014 Annual Scientific...

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral D...

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density Romosozumab...

New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patien...

New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset...

UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)

UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol) - Dermira obtains...

Securities Registration (ads, Immediate) (f-6ef)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

UCB Announces Data from First Seven Year Evaluation of Cimzia® (certolizumab pegol) in Moderate to Severe Crohn's Disease Pa...

UCB Announces Data from First Seven Year Evaluation of Cimzia® (certolizumab pegol) in Moderate to Severe Crohn's Disease Patients - The...

First Results Presented from Study of U.S. Veterans Using a Health Data Sharing Network Show Measurable Improvements in Epile...

First Results Presented from Study of U.S. Veterans Using a Health Data Sharing Network Show Measurable Improvements in Epilepsy...

Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At B...

Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip PR...

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at 2013 American College of Rheumatology Annual Scienti...

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at 2013 American College of Rheumatology Annual Scientific Meeting PR...

New Study Shows Effect of Neupro® (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs ...

New Study Shows Effect of Neupro® (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome Data Showed...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB (PK) (UCBJY)

Outils de qualité professionnelle, pour des investisseurs individuels.

UCBJY Actualités

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at American College of Gastroenterology 2014 Annual Sci...

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral D...

New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patien...

UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)

Securities Registration (ads, Immediate) (f-6ef)

UCB Announces Data from First Seven Year Evaluation of Cimzia® (certolizumab pegol) in Moderate to Severe Crohn's Disease Pa...

First Results Presented from Study of U.S. Veterans Using a Health Data Sharing Network Show Measurable Improvements in Epile...

Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At B...

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at 2013 American College of Rheumatology Annual Scienti...

Cimzia® (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis

UCB highlights educational support programs for people living with Parkinson's disease at the World Parkinson Congress

Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis

UCB's Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride

Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

New Study Shows Effect of Neupro® (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs ...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB (PK) (UCBJY) Actualités

UCB (PK) (UCBJY)

Outils de qualité professionnelle, pour des investisseurs individuels.

UCBJY Actualités

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at American College of Gastroenterology 2014 Annual Sci...

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral D...

New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patien...

UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)

Securities Registration (ads, Immediate) (f-6ef)

UCB Announces Data from First Seven Year Evaluation of Cimzia® (certolizumab pegol) in Moderate to Severe Crohn's Disease Pa...

First Results Presented from Study of U.S. Veterans Using a Health Data Sharing Network Show Measurable Improvements in Epile...

Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At B...

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at 2013 American College of Rheumatology Annual Scienti...

Cimzia® (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis

UCB highlights educational support programs for people living with Parkinson's disease at the World Parkinson Congress

Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis

UCB's Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride

Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

New Study Shows Effect of Neupro® (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs ...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application